327 related articles for article (PubMed ID: 31027511)
1. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mohsen MO; Heath MD; Cabral-Miranda G; Lipp C; Zeltins A; Sande M; Stein JV; Riether C; Roesti E; Zha L; Engeroff P; El-Turabi A; Kundig TM; Vogel M; Skinner MA; Speiser DE; Knuth A; Kramer MF; Bachmann MF
J Immunother Cancer; 2019 Apr; 7(1):114. PubMed ID: 31027511
[TBL] [Abstract][Full Text] [Related]
2. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.
Cabral-Miranda G; Heath MD; Mohsen MO; Gomes AC; Engeroff P; Flaxman A; Leoratti FMS; El-Turabi A; Reyes-Sandoval A; Skinner MA; Kramer MF; Bachmann MF
Vaccines (Basel); 2017 May; 5(2):. PubMed ID: 28468322
[TBL] [Abstract][Full Text] [Related]
3. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
4. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
5. In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.
Mohsen MO; Heath M; Kramer MF; Velazquez TC; Bullimore A; Skinner MA; Speiser DE; Bachmann MF
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100311
[TBL] [Abstract][Full Text] [Related]
6. DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines.
Cabral-Miranda G; M Salman A; O Mohsen M; L Storni F; S Roesti E; A Skinner M; D Heath M; F Kramer M; M Khan S; J Janse C; V S Hill A; F Bachmann M
Diseases; 2018 Nov; 6(4):. PubMed ID: 30469323
[TBL] [Abstract][Full Text] [Related]
7. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
9. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
10. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
12. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
[TBL] [Abstract][Full Text] [Related]
13. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
Cárdenas-Vargas A; Elizondo-Quiroga D; Gutierrez-Ortega A; Charles-Niño C; Pedroza-Roldán C
Viral Immunol; 2016 Dec; 29(10):557-564. PubMed ID: 27834623
[TBL] [Abstract][Full Text] [Related]
15. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
16. Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid.
Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; El-Baky NA; Redwan EM
Hum Antibodies; 2018 Feb; 26(2):75-85. PubMed ID: 29171990
[TBL] [Abstract][Full Text] [Related]
17. Adjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating.
Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; Redwan EM
Hum Antibodies; 2017; 25(1-2):23-29. PubMed ID: 27858706
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.
Heath MD; Swan NJ; Marriott AC; Silman NJ; Hallis B; Prevosto C; Gooch KE; Skinner MA
BMC Infect Dis; 2017 Mar; 17(1):232. PubMed ID: 28347293
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.
McKee SJ; Young VL; Clow F; Hayman CM; Baird MA; Hermans IF; Young SL; Ward VK
J Control Release; 2012 May; 159(3):338-45. PubMed ID: 22386518
[TBL] [Abstract][Full Text] [Related]
20. Golden-star nanoparticles as adjuvant effectively promotes immune response to foot-and-mouth disease virus-like particles vaccine.
Teng Z; Sun S; Chen H; Huang J; Du P; Dong H; Xu X; Mu S; Zhang Z; Guo H
Vaccine; 2018 Oct; 36(45):6752-6760. PubMed ID: 30268733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
